Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mansoura Univ. EGFR compound 25: sourced facts only. name: "Compounds 21 and 25 were the best EGFR inhibitors having IC50 values of 0.077 and 0.059 µM, respectively, in comparison to Erlotinib (IC50 = 0.04 µM)." [PMID:39912365]; target: "Compounds 21 and 25 were the best EGFR inhibitors having IC50 values of 0.077 and 0.059 µM, respectively, in comparison to Erlotinib (IC50 = 0.04 µM)." [PMID:39912365]; developer: "Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt." [PMID:39912365]; stage: "Finally, compound 25, which was found to be the best dual inhibitor against EGFR and FGFR, was tested for inducing apoptosis and affecting cellular arrest within G2/M phase as well as it was screened to measure its safety towards normal breast cells MCF10a with IC50 value of 47.16 µM in contrast to the reference Staurosporine (IC50 = 18.86 µM)." [PMID:39912365]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mansoura Univ. EGFR compound 25.